Navigation Links
GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
Date:9/11/2007

ST. JOSEPH, Mich., Sept. 11 /PRNewswire/ -- GeneGo, Inc. and the Cystic Fibrosis Foundation announced today their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data. GeneGo's proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases.

"We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "Using computational platforms adds to our arsenal of already existing strategies."

The new platform, called MetaMiner (CF), will include off-the-shelf GeneGo products such as MetaCore, MetaDrug, MetaLink and MapEditor. Platforms such as MetaDrug can help to solve various problems including a drug's mechanism of action, toxicity and off-target effects, deduced from the structure and any kind of supplementary omics data. The product is intended to be used by medicinal chemists and biologists active in pre-clinical areas of high content and high throughput screening, bioassays, hit-to-lead. MetaMiner (CF) will include cystic fibrosis-specific OMICs and small experiments content annotated by GeneGo, disease maps and networks.

"We are very pleased to work with Cystic Fibrosis Foundation and the academic community which is very well organized and successful in research and drug discovery for the disease. We have a clear direction and end goals that we are focused on," said Julie Bryant, GeneGo's vice president of business development. "This collaboration is the first in the series of disease-centered MetaMiner projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project."

The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses.

Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene.

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com. MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and supports and accredits a nationwide network of 115 CF care centers, including 94 adult programs, which provide vital treatments and other CF resources to patients and families. For more information, visit http://www.cff.org.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Third Wave seeks approval of Cystic Fibrosis test
2. EraGen cystic fibrosis test to be distributed worldwide through Bayer
3. Third Wave strikes deal with Kaiser Permanente on cystic fibrosis reagents
4. Entrepreneurship grant will build strong foundation
5. UWM launches research foundation
6. NorthStar signs exclusive agreement with Illinois foundation
7. SBC Foundation awards technology grants in Wisconsin
8. SBC foundation gives Excelerator grants to local nonprofits
9. Hendee promoted to president of MCW Research Foundation; Gutterman steps up
10. Rennebohm foundation gives $15m to UW for medical research
11. Stem-cell research gets grant from M.J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... Franz Inc ., an early innovator ... market leader for Semantic Graph Database technology, today announced Allegro ... effective system for developing and deploying applications to solve the challenges developers face ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. Schwartz, ... proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the practice ... , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert ...
(Date:4/24/2017)... ... April 24, 2017 , ... It ... a cellular milieu; however, the broad application of this cellular target engagement concept ... sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, ...
(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... Having ... than a year, Formaspace is pleased to introduce it to top lab design architects ... Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey will ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):